)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
bioAffinity Technologies
bioAffinity Technologies (BIAF) investor relations material
bioAffinity Technologies Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary6 Nov, 2026
Executive summary
CyPath® Lung 9M test volume reached ~1,600 vs. 775 YoY, with revenue up 79% to $1.1M; total revenue fell as unprofitable pathology services were discontinued.
9M net loss widened to $12.27M from $11.77M; management cited substantial doubt about the ability to continue as a going concern for at least 12 months after issuance.
Growth initiatives included broader physician use, VA and military trial enrollment, government-market distribution, and research in asthma, COPD and skin cancer therapeutics.
Financial highlights
Q3 revenue was $1.07M vs. $1.45M YoY; operating loss was $3.51M vs. $2.29M, and net loss was $5.28M vs. $5.05M.
9M revenue was $3.93M vs. $4.57M; operating loss was $10.46M vs. $7.44M, and net loss was $12.27M vs. $11.77M.
Q3 CyPath® Lung revenue was $273K vs. $296K; 526 test results were delivered vs. 385, with lower average reimbursement offsetting volume growth.
Q3 operating expenses rose to $4.58M from $3.74M; 9M CyPath® Lung unit sales grew 100% YoY, and ordering physicians increased 89% in Q3 YoY.
Outlook and guidance
Cash and cash equivalents were $2.55M at Sept. 30 and $4.6M at Nov. 3 following financing; resources were expected to support operations through March 2027.
Continued losses and negative operating cash flows are expected; additional capital is needed, and without funding, development may be curtailed or operations may cease.
Priorities include disciplined execution, broader CyPath® Lung adoption, clinical and research programs, and development of topical skin cancer therapeutics; further validation is needed for post-treatment surveillance and asthma/COPD applications.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from bioAffinity Technologies
- Warrant approvals, a capped financing mandate, and a proposed authorized-share cut are on the ballot.BIAF
Proxy filing - Five proposals seek warrant-exercise funding, future offering authority, and fewer authorized shares.BIAFProxy filing
- Shareholders will vote on key capital and share structure proposals to support future growth.BIAFProxy filing
- CyPath Lung's rapid adoption highlights a breakthrough in early lung cancer detection.BIAFH.C. Wainwright 28th Annual Global Investment Conference
- Diagnostic company seeks capital via warrant-linked share offering amid ongoing losses and market risks.BIAFRegistration filing
- AI-driven lung diagnostics firm offers 1.7M shares for resale; proceeds support working capital.BIAFRegistration filing
- Q2 2026 saw 216% CyPath® Lung test growth and 19% revenue increase, but liquidity risks remain.BIAFQ2 2026
- Common stock and pre-funded warrants offered via placement agent with standard protections.BIAFRegistration filing
- CyPath Lung streamlines nodule risk assessment, reducing unnecessary biopsies and patient anxiety.BIAFStatus update
Next bioAffinity Technologies earnings date
Q4 202612 Mar, 2027
bioAffinity Technologies
Next bioAffinity Technologies earnings date
Q4 202612 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
bioAffinity Technologies Inc. is a biotechnology company focused on addressing the critical need for non-invasive, early-stage cancer diagnosis and targeted cancer treatments. The company's flagship product, CyPath Lung, is a diagnostic test for the early detection of lung cancer. Additionally, the company is involved in research and development efforts aimed at creating targeted diagnostics and therapeutics to combat cancer, leveraging its core porphyrin platform technology. The company is headquartered in is headquartered in San Antonio, Texas, and its shares are listed on the Nasdaq.